Washburn et al., 2006 - Google Patents
A novel three‐dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic studyWashburn et al., 2006
View PDF- Document ID
- 561365764126522942
- Author
- Washburn W
- Teperman L
- Heffron T
- Douglas D
- Gay S
- Katz E
- Klintmalm G
- Publication year
- Publication venue
- Liver transplantation
External Links
Snippet
This study evaluated the pharmacokinetics and pharmacodynamics of a novel 3‐dose regimen of daclizumab in de novo hepatitis C liver transplant recipients. In 30 of 156 recipients receiving daclizumab, mycophenolate mofetil, tacrolimus, and no steroids (Arm 3 …
- 108010084740 Daclizumab 0 title abstract description 106
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11982670B2 (en) | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy | |
| Zhang et al. | Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction | |
| Jucaud et al. | Prevalence and impact of de novo donor‐specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients | |
| Okochi et al. | Observations on Australia antigen in Japanese | |
| Hauser et al. | Natural killer cell activity in multiple sclerosis. | |
| Gorbacheva et al. | Memory CD4 T cells induce antibody-mediated rejection of renal allografts | |
| JP6728047B2 (en) | Treatment methods and compositions | |
| Honda et al. | De novo membranous nephropathy and antibody‐mediated rejection in transplanted kidney | |
| RU2679913C2 (en) | Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction | |
| US20130028890A1 (en) | Method for detecting regulatory t cells using expression of folate receptor 4 as indicator, method for treating diseases using the detection method, pharmaceutical composition for immunostimulation, and method for treating diseases using the composition | |
| JP2005106694A (en) | Early detection and severity assessment of sepsis | |
| Salah et al. | Application of complement component 4d immunohistochemistry to ABO‐compatible and ABO‐incompatible liver transplantation | |
| Lankisch et al. | Antinuclear and pancreatic acinar cell antibodies in pancreatic diseases | |
| Boleslawski et al. | CD28 expression by peripheral blood lymphocytes as a potential predictor of the development of de novo malignancies in long‐term survivors after liver transplantation | |
| Citterio et al. | C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients | |
| Wasi et al. | Serum-immunoglobulin levels in thalassaemia and the effects of splenectomy | |
| EP2538217A1 (en) | Method of identifying risk for thyroid disorder | |
| Utsumi et al. | Risk analysis for invasive fungal infection after living donor liver transplantation: which patient needs potent prophylaxis? | |
| Washburn et al. | A novel three‐dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study | |
| Xing et al. | Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: A prospective controlled study | |
| CN120129835A (en) | Diagnosis of immune-mediated inflammatory diseases using MMP12 as an indicator, and therapeutic drugs for immune-mediated inflammatory diseases based on inhibition of MMP12 | |
| Mizokami et al. | Human T-lymphotropic virus type I-associated uveitis in patients with Graves' disease treated with methylmercaptoimidazole | |
| Adams et al. | Biliary β2-microglobulin in liver allograft rejection | |
| Delaney et al. | Constitutive and acquired resistance to calcineurin inhibitors in renal transplantation: role of P‐glycoprotein‐170 | |
| US20250044280A1 (en) | Methods for diagnosing or predicting a cardiac inflammatory condition |